DUBAI, UAE /PRNewswire/ -- Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet Avigan®/Reeqonus™, a drug being used in several countries to treat patients with mild to moderate cases of COVID-19.
"Over the course of a year, GRA has signed a global licensing agreement for Avigan® with its developer, FujiFilm Toyama, filed a drug dossier with various regulators, and recently initiated a global Phase 3 clinical trial in an outpatient setting," said GRA CEO Mitch Wilson. "Working closely with our strategic partner Dr. Reddy's, we've taken major steps toward our goal of providing an affordable, easily administered, widely available oral anti-viral to help in the fight against this global pandemic."
Together with Dr. Reddy's Laboratories (NYSE: RDY), GRA is part of a consortium of companies that has been collaborating on the international development and distribution of Avigan®/Reeqonus™ for treatment and prevention of COVID-19 since October 2020. The consortium has generated $33 million in revenue through sales of Avigan® to pharmaceutical distributors and governments in secondary markets around the world.
Wilson said the steady increase in sales across a growing number of countries where Avigan® has been approved to treat COVID-19 "demonstrates that we are not alone in our hope that Avigan® can contribute in the battle to save lives."
Countries purchasing Avigan® based on regulatory approval of the therapy for the treatment of COVID-19 include Indonesia, Malaysia, Thailand and India. In a separate deal with FujiFilm, the Japanese government recently placed an order to stockpile over 65 million tablets.
Avigan® is a broad-spectrum anti-viral in oral tablet form developed by FujiFilm Toyama Chemical and approved in Japan as a treatment and stockpile countermeasure for pandemic influenza. Over the past year, the consortium has collaborated to evaluate Avigan® as an investigational therapy for early onset COVID-19 patients.
As recently announced by GRA, a Phase 3 US-Canada clinical trial of the anti-viral yielded a positive interim outlook. The group will continue evaluating the efficacy of Avigan® for treatment of patients with mild to moderate cases of COVID-19, and will publish results in Q3 2021.
-Ends-
About Global Response Aid (GRA)
Agility (KSE/DFM: AGLTY), one of the world's leading logistics companies and AiPharma, an innovative pharma research, development and commercialization company based in Dubai, established Global Response Aid (GRA) to address the market challenges created by the COVID-19 pandemic and other threats to public health. GRA delivers innovative, effective healthcare solutions through a range of pharmaceutical products and technology platforms. It works closely with governments, regulatory authorities, hospitals, clinics, healthcare providers, life sciences companies, NGOs and public institutions to develop strategies that allow them to tackle public health challenges.
For more information: www.globalresponseaid.com
About Dr. Reddy's
Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe.
For more information: www.drreddys.com
About FUJIFILM
FUJIFILM Corporation, Tokyo, Japan is one of the major operating companies of FUJIFILM Holdings Corporation. The company brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship.
For more information holdings.fujifilm.com
CONTACT:
Mary O'Brien
Chief Marketing Officer
Global Response Aid
mary@globalresponseaid.com
+971 48325557
SOURCE Global Response Aid
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
